Physician profile
Cathleen Marshall
NPI 1083957070
$988.77
in general payments reported to CMS, 2019-2025
13 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Neurodevelopmental Disabilities (Psychiatry & Neurology) provider received nationally (typical 2025 total: $328).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.54 · 2021: $14.76 · 2023: $194 · 2024: $303 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $892 · Education: $41.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $891.97 |
| Education | $41.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $273.25 | 2023-2025 | |
| Corium, LLC | $160.01 | 2023-2024 | Azstarys |
| Sanofi-Aventis U.S. LLC | $121.77 | 2024-2025 | |
| Ucb, INC. | $92.17 | 2025 | Fintepla |
| Acadia Pharmaceuticals INC | $87.26 | 2024-2025 | Daybue |
| Neurelis, INC. | $71.80 | 2021-2024 | Valtoco |
| Genentech USA, INC. | $40.54 | 2019 | |
| Pfizer INC. | $39.63 | 2023 | |
| Alexion Pharmaceuticals, INC. | $27.05 | 2024 | |
| Catalyst Pharmaceuticals, INC. | $25.06 | 2025 | |
| Tg Therapeutics, INC. | $24.50 | 2025 | |
| Ironshore Pharmaceuticals INC. | $13.16 | 2024 | |
| Harmony Biosciences LLC | $12.57 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathleen Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.